Page last updated: 2024-12-08

antiflammin p1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

antiflammin P1: nonapeptide fragment of uteroglobin has no phospholipase A2 inhibitory & anti-inflammatory activity; RN given refers to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164083
MeSH IDM0178055

Synonyms (8)

Synonym
antiflammin p1
met-gln-met-lys-lys-val-leu-asp-ser
methionyl-glutaminyl-methionyl-lysyl-lysyl-valyl-leucyl-aspartyl-serine
l-serine, n-(n-(n-(n-(n2-(n2-(n-(n2-l-methionyl-l-glutaminyl)-l-methionyl)-l-lysyl)-l-lysyl)-valyl)-l-leucyl)-l-alpha-aspartyl)-
mqmkkvlds
antiflamin 1
antiflammin 1
(3s)-3-[[2-[[(2s)-2-[[6-amino-2-[[(2s)-6-amino-2-[[2-[[(2s)-5-amino-2-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-[[(
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (47.83)18.2507
2000's9 (39.13)29.6817
2010's3 (13.04)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.09 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (26.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (73.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]